AndhraNews.net
Home » Business News » 2012 » July » July 9, 2012

Thrombogenics CEO Discusses Product Pipeline Ahead of Catalyts, FDA Review


July 9, 2012 - London

In an exclusive interview with PropThink.com, Thrombogenics (EBR:THR)(OTC:TBGNF) CEO Patrik De Haes discusses the company's pending FDA and EMA approvals of ocriplasmin, a treatment for symptomatic vitreomacular adhesion. Current procedures in the 500,000 patient market require a week-long recovery period in which the patient remains immobilized face-down. Ocriplasmin, says De Haes, is an outpatient treatment that requires one injection and no recovery time. Not only is it faster, but De Haes says the injection may cost as little as $2000, a fraction of the current $10,000 standard. He expects a late summer approval and commercialization in the U.S. and Europe - with a helping hand from partner Alcon, a division of Novartis (NYSE:NVS) - in Q1 of 2013.

De Haes also discusses results from studies of Thrombogenics' pipeline drug TB-402, a post-surgery anticoagulant that has shown increased efficacy and similar safety to Xarelto by Bayer (OTC:BAYRY), and Lovenox by Sanofi (NYSE:SNY).  

To see the full video interview with Thrombogenics CEO Patrik De Haes, click here.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com





This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PropThink via Thomson Reuters ONE

HUG#1625210

GlobeNewswire

Comment on this story

Share